Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionFirst Pacific Financial
Latest Disclosed Ownership1,420 shares
Latest Disclosed Value $ 634,087
First Pacific Financial reports 0.57% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 23, 2026 - First Pacific Financial filed a 13F-HR form disclosing ownership of 1,420 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $634,087 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 1,412 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.57% during the quarter. The current value of the position is $608,243 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,420 8 0.57 634 -0.94 0.0817
2026-01-16 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,412 -39 -2.69 640 12.68 0.0836
2025-10-21 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,451 -14 -0.96 568 -12.88 0.0789
2025-07-18 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,465 -116 -7.34 652 -14.88 0.0961
2025-04-23 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,581 -144 -8.35 767 10.37 0.1555
2025-01-15 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,725 747 76.38 695 52.86 0.1616
2024-10-15 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 978 54 5.84 455 4.85 0.1064
2024-07-19 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 924 26 2.90 433 15.47 0.1113
2024-04-24 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 898 62 7.42 375 10.29 0.1049
2024-01-18 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 836 53 6.77 340 25.00 0.1039
2023-10-23 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 783 162 26.09 272 24.77 0.1214
2023-08-08 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 621 621 219 0.0927
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.